<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30186139</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">1662-6575</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>11</Volume>                    <Issue>2</Issue>                    <PubDate>                        <MedlineDate>2018 May-Aug</MedlineDate>                    </PubDate>                </JournalIssue>                <Title>Case reports in oncology</Title>                <ISOAbbreviation>Case Rep Oncol</ISOAbbreviation>            </Journal>            <ArticleTitle>Aromatase Inhibitor-Associated Tendinopathy and Muscle Tendon Rupture: Report of Three Cases of This Exceedingly Rare Adverse Event.</ArticleTitle>            <Pagination>                <MedlinePgn>557-561</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1159/000491874</ELocationID>            <Abstract>                <AbstractText>Aromatase inhibitors (AIs) are a commonly used antihormonal therapy in the treatment of breast cancer in postmenopausal women, specifically in the treatment of hormone receptor-positive breast cancer. AI-associated tendinopathy and muscle tendon rupture is exceedingly rare. Until now, only one case with AI-associated severe tendinopathy has been reported in the medical literature, and there are no recorded cases of AI-associated muscle tendon rapture. We report three cases of postmenopausal women with hormone receptor-positive breast cancer, who experienced tendinopathy or muscle tendon rupture under antihormonal treatment with letrozole. All of the three women were in the adjuvant setting, and the treatment of tendinopathy or tendon rupture consisted of AI discontinuation, initiation of corticosteroids, or surgical treatment. Diagnosis was made via MRI. Furthermore, in our cases, there were no signs of underlying systemic disease, there was no abnormal physical activity preceding the complaints, and there was no use of other drugs beside letrozole. AIs are one of the most commonly used drugs in antihormonal therapy for hormone receptor-positive breast cancer. In every case of a female patient with hormone receptor-positive breast cancer under treatment with AIs and arthralgia, an MRI should be performed in order to exclude the presence of tendinopathy or muscle tendon rupture.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Mitsimponas</LastName>                    <ForeName>Nikolaos</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Second Oncological Clinic, Agios Savvas Hospital, Athens, Greece.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Klouva</LastName>                    <ForeName>Evangelia</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Second Oncological Clinic, Agios Savvas Hospital, Athens, Greece.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tryfonopoulos</LastName>                    <ForeName>Dimitrios</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Second Oncological Clinic, Agios Savvas Hospital, Athens, Greece.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Grivas</LastName>                    <ForeName>Anastasios</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Second Oncological Clinic, Agios Savvas Hospital, Athens, Greece.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Demiri</LastName>                    <ForeName>Stamatina</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Second Oncological Clinic, Agios Savvas Hospital, Athens, Greece.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Koumakis</LastName>                    <ForeName>George</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Second Oncological Clinic, Agios Savvas Hospital, Athens, Greece.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gouveris</LastName>                    <ForeName>Panagiotis</ForeName>                    <Initials>P</Initials>                    <AffiliationInfo>                        <Affiliation>Second Oncological Clinic, Agios Savvas Hospital, Athens, Greece.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>17</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Case Rep Oncol</MedlineTA>            <NlmUniqueID>101517601</NlmUniqueID>            <ISSNLinking>1662-6575</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Rheumatology (Oxford). 2004 Feb;43(2):131-42</RefSource>                <PMID Version="1">12867575</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2006 Aug;7(8):633-43</RefSource>                <PMID Version="1">16887480</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2007 Jul;104(1):87-91</RefSource>                <PMID Version="1">17061044</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2002 Feb 1;20(3):751-7</RefSource>                <PMID Version="1">11821457</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Breast Cancer. 2007 Oct;7(10):775-8</RefSource>                <PMID Version="1">18021478</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Rheumatology (Oxford). 2007 Oct;46(10):1619-21</RefSource>                <PMID Version="1">17726034</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2011 Mar 14;13(2):205</RefSource>                <PMID Version="1">21457526</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 1998 Sep;4(9):2089-93</RefSource>                <PMID Version="1">9748124</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2014 Aug 15;120(16):2403-11</RefSource>                <PMID Version="1">24802413</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Menopause. 2013 Feb;20(2):162-8</RefSource>                <PMID Version="1">22990756</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2015 Oct 3;386(10001):1341-1352</RefSource>                <PMID Version="1">26211827</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2003 Jun 12;348(24):2431-42</RefSource>                <PMID Version="1">12802030</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Aromatase inhibitor</Keyword>            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Muscle tendon rupture</Keyword>            <Keyword MajorTopicYN="N">Tendinopathy</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>05</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>05</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>9</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30186139</ArticleId>            <ArticleId IdType="doi">10.1159/000491874</ArticleId>            <ArticleId IdType="pii">cro-0011-0557</ArticleId>            <ArticleId IdType="pmc">PMC6120376</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>